TROG Cancer Research
Members Login   CQMS Login

COVID-19 TROG Cancer Research Update


The situation around the COVID-19 pandemic is rapidly changing.

Like many other businesses, TROG Cancer Research is adapting to this situation to ensure the safety and welfare of staff, whilst aiming to limit interruptions to our business operations.

Some of those measures include:

  • All TROG Cancer Research Staff are working from home until further notice, resulting in the Central Operations Office being unattended. This move has been managed by the TROG Central Operations Team without impacting on TROG’s service capability
  • Due to the office being unattended, we have placed an outgoing message on the phone line asking callers to email the person they wish to contact. Should anyone have an urgent matter whereby they need to speak to a TROG Central Operations staff member, they are advised to phone 0414 308 277 and speak to Administration in the first instance. The Central Operations Office phone will not be checked for messages.
  • Email is the most effective method of communication at this time, and emails will be attended to during business hours as per usual email:
  • Face-to-face meetings have been replaced with phone or video conferencing until further notice.

During the COVID-19 pandemic we are continually assessing how to approach each individual clinical trial to ensure the safety of trial participants whilst maintaining compliance with GCP and minimising risks to trial integrity. 

In collaboration with our TROG Scientific Committee and Trial Management Committees, we are working to provide guidance to all sites and Investigators regarding advice for trial conduct during this challenging time. More information will follow.

TROG Cancer Research appreciate your ongoing support and understanding as we all work through this challenging time together.

As the COVID-19 situation evolves we will update you on any changes.

If you have any questions, please don’t hesitate to contact us via email:

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.